The eIF2-alpha kinase HRI: a potential target beyond the red blood cell

Introduction: The eIF2 kinase heme-regulated inhibitor (HRI) is one of four well-described kinases that phosphorylate eIF2 in response to various cell stressors, resulting in reduced ternary complex formation and attenuation of mRNA translation. Although HRI is well known for its role as a heme sensor in erythroid progenitors, pharmacologic activation of HRI has been demonstrated to have anti-cancer activity across a wide range of tumor sub-types. Here, the potential of HRI activators as novel cancer therapeutics is explored.Areas covered: We provide an introduction to eIF2 signaling pathways in general, and specifically review data on the eIF2 kinase HRI in erythroid and non-erythroid cells. We review aspects of targeting eIF2 signaling in cancer and highlight promising data using HRI activators against tumor cells.Expert opinion: Pharmacologic activation of HRI inhibits tumor growth as a single agent without appreciable toxicity in vivo. The ability of HRI activators to provide direct and sustained eIF2 phosphorylation without inducing oxidative stress or broad eIF2 kinase activation may be especially advantageous for tolerability. Combination therapy with established therapeutics may further augment anti-cancer activity to overcome disease resistance.